Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 6 · 100%Low 0 · 0%Moderate 0 · 0%High 0 · 0%

Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP)

HIV‐Transmission or Death at 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31

It is very uncertain whether bae: AZT/3TC/NVP changes HIV‐Transmission or Death at 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.39 [0.18, 0.85]
1 study · 178 participants
Very low

Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP)

Infant Grade 3/4 Severe Adverse Events at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31

It is very uncertain whether bae: AZT/3TC/NVP changes infant Grade 3/4 Severe Adverse Events at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 1.26 [0.35, 4.54]
1 study · 178 participants
Very low

Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP)

Prematurity · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31

It is very uncertain whether bae: AZT/3TC/NVP changes prematurity compared with AZT (+/‐ single dose NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.56 [0.21, 1.5]
1 study · 178 participants
Very low

Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP)

Mother to Child Transmission at Birth · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31

It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at Birth compared with AZT (+/‐ single dose NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.18 [0.02, 1.36]
1 study · 178 participants
Very low

Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP)

Mother to Child Transmission at 1 Month · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31

It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission at 1 Month compared with AZT (+/‐ single dose NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.23 [0.05, 0.96]
1 study · 178 participants
Very low

Bae: AZT/3TC/NVP vs AZT (+/‐ single dose NVP)

Mother to Child Transmission Cumulative by 7 Months · HIV‐infected pregnant women with CD4 Counts <200 cells/mm31

It is very uncertain whether bae: AZT/3TC/NVP changes mother to Child Transmission Cumulative by 7 Months compared with AZT (+/‐ single dose NVP) (very low certainty).

1 finding from 1 review

Antiretroviral therapy (ART) for treating HIV infection in ART‐eligible pregnant women 2010 · Cochrane Headline outcomes only
RR 0.15 [0.04, 0.62]
1 study · 178 participants
Very low